Use of GLP-1 or analogs to abolish catabolic changes after surgery

• US 6,006,753 A
• Filed: 08/21/1997
• Issued: 12/28/1999
• Est. Priority Date: 08/30/1996
• Status: Expired due to Term

• Current Assignee: Eli Lilly and Company
• Original Assignee: Eli Lilly and Company
• Inventors: Efendic, Suad
• Primary Examiner(s): Yu, Mickey
• Assistant Examiner(s): Nguyen, Dinh X.
• Application Number:
  US08/916,991
• Time in Patent Office: 859 Days
• Field of Search: 128/897, 128/898, 514/772.3, 514/2, 514/3, 530/303, 530/308
• US Class Current: 128/898
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin
• CPC Class Codes: C07K 14/605 Glucagons

Abstract

This invention provides a method of attenuating post-surgical catabolic changes and hormonal responses to stress. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.

Claims

1. A method of attenuating post-surgical catabolic changes and insulin resistance, comprising, administering to a patient in need thereof a compound selected from the group consisting of GLP-1, GLP-1 analogs, GLP-1 derivatives, and pharmaceutically-acceptable salts thereof.

2. The method of claim 1, wherein the compound is administered intravenously.

3. The method of claim 1, wherein the compound is administered subcutaneously.

4. The method of claims 2 or 3, wherein the administration is continuous.

5. The method of claim 4 wherein the rate of administration of the compound is between 0.25 and 6 pmol/kg/min.

6. The method of claim 5 wherein the rate of administration of the compound is between 0.5 and 2.4 pmol/kg/min.

7. The method of claim 5 wherein said rate is between about 0.5 and about 1.2 pmol/kg/min.

8. The method of claim 2 wherein the intravenous administration is intermittent.

9. The method of claim 2 wherein the compound is administered intravenously and also administered by another parenteral route.

10. The method of claim 9 wherein the other parenteral route is the subcutaneous route.

11. The method of claim 1 wherein the compound administered is GLP(7-36) amide, or a pharmaceutically-acceptable salt thereof.

12. A method of attenuating post-surgical catabolic changes and hormonal responses to stress, comprising, administering to a patient in need thereof a compound that exerts insulinotropic activity by interacting with the same receptor, or receptors, with which GLP-1, GLP-1 analogs, and GLP-1 derivatives interact in exerting their insulinotropic activity.

13. A method of attenuating post-surgical catabolic changes and hormonal responses to stress, comprising, administering a compound that enhances insulin sensitivity by interacting with the same receptor, or receptors, with which GLP-1, GLP-1 analogs, and GLP-1 derivatives interact to enhance insulin sensitivity.